Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial

The Lancet Oncology

Volumn 16, Issue 5, 2015, Pages 522-530

  Eggermont, Alexander M M ^a   Chiarion Sileni, Vanna ^b   Grob, Jean Jacques ^c   Dummer, Reinhard ^d   Wolchok, Jedd D ^e   Schmidt, Henrik ^f   Hamid, Omid ^g   Robert, Caroline ^a   Ascierto, Paolo A ^h   Richards, Jon M ⁱ   Lebbé, Céleste ^j   Ferraresi, Virginia ^k   Smylie, Michael ^l   Weber, Jeffrey S ^m   Maio, Michele ⁿ   Konto, Cyril ^o   Hoos, Axel ^o   de Pril, Veerle ^o   Gurunath, Ravichandra Karra ^p   de Schaetzen, Gaetan ^p   Suciu, Stefan ^p   Testori, Alessandro ^q   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c AIX MARSEILLE UNIVERSITY   (France)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g Angeles Clinic and Research Institute   (United States)

^h NATIONAL CANCER INSTITUTE   (Italy)

ⁱ Oncology Specialists SC   (United States)

^j SAINT LOUIS HOSPITAL   (France)

^k Istituti Fisioterapici Ospitalieri Rome   (Italy)

^l CROSS CANCER INSTITUTE   (Canada)

^m H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁿ UNIVERSITY HOSPITAL OF SIENA   (Italy)

^o BRISTOL MYERS SQUIBB   (United States)

^p EORTC DATA CENTER   (Belgium)

^q EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IPILIMUMAB; PLACEBO; TUMOR NECROSIS FACTOR ANTIBODY; IMMUNOLOGICAL ADJUVANT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; COUGHING; CUTANEOUS MELANOMA; DECREASED APPETITE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISTANT METASTASIS FREE SURVIVAL; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL DISEASE; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPERTRANSAMINASEMIA; HYPOPHYSITIS; HYPOTHYROIDISM; IMMUNOPATHOLOGY; INTENTION TO TREAT ANALYSIS; INTERACTIVE VOICE RESPONSE SYSTEM; LIVER DISEASE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; MYOCARDITIS; NAUSEA; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN SURGERY; TREATMENT OUTCOME; ULCERATIVE COLITIS; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TUMOR RECURRENCE;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL;

EID: 84933678156     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)70122-1     Document Type: Article

References (23)

1. Eggermont AMM, Spatz A, Robert C Cutaneous melanoma. Lancet 2014, 383:816-827.
2. Balch CM, Gershenwald JE, Soong S-J, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199-6206.
3. Balch CM, Gershenwald JE, Soong S-J, et al. Multivariate analysis of prognostic factors among 2313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 2010, 28:2452-2459.
4. Romano E, Scordo M, Dusza SW, Coit DG, Chapman PB Site and timing of first relapse in stage III melanoma patients: Implications for follow-up guidelines. J Clin Oncol 2010, 28:3042-3047.
5. van Akkooi ACJ, Nowecki ZI, Voit C, et al. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes. Ann Surg 2008, 248:949-955.
6. van der Ploeg APT, van Akkooi ACJ, Rutkowski P, et al. Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol 2011, 29:2206-2214.
7. van der Ploeg AP, van Akkooi AC, Haydu LE, et al. The prognostic significance of sentinel node tumour burden in melanoma patients: An international, multicenter study of 1539 sentinel node-positive melanoma patients. Eur J Cancer 2014, 50:111-120.
8. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
9. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526.
10. Lebbé C, Weber JS, Maio M, et al. Survival follow-up and ipilimumab retreatment for patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann Oncol 2014, 25:2277-2284.
11. Suciu S, Ives N, Eggermont AM, et al. Predictive importance of ulceration on the efficacy of adjuvant interferon-a (IFN): An individual patient data (IPD) meta-analysis of 15 randomized trials in more than 7,500 melanoma patients (pts). Proc Am Soc Clin Oncol 2014, 32(suppl). (abstr) 9067.
12. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003, 29:241-252.
13. Mocellin S, Pasquali S, Rossi CR, Nitti D Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010, 102:493-501.
14. Pocock SJ, Simon R Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975, 31:103-115.
15. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010, 11:155-164.
16. Eggermont AMM, Suciu S, MacKie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005, 366:1189-1196.
17. Eggermont AMM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008, 372:117-126.
18. Eggermont AM, Suciu S, Testori A, et al. Long term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol 2012, 30:3810-3818.
19. Eggermont AMM, Suciu S, Testori A, et al. Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 2012, 48:218-225.
20. Spatz A, Cook MG, Elder DE, Piepkorn M, Ruiter DJ, Barnhill RL Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas. Eur J Cancer 2003, 39:1861-1865.
21. Winnepenninckx V, Lazar V, Michiels S, et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 2006, 98:472-482.
22. Elliott B, Scolyer RA, Suciu S, et al. Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. Clin Cancer Res 2007, 13:3825-3830.
23. Eggermont AM, Spatz A, Lazar V, Robert C Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?. Curr Opin Oncol 2012, 24:137-140.